REGENERON PHARMACEUTICALS, INC. REGN

Latest FY: 2025 Healthcare Biotechnology
Market Price $793.26
Market Cap $83.16B
P/E Ratio 19.12
Quick Peer Compare (Healthcare):
Revenue (FY 2025) ↑1.0% YoY
$14.34B
3-Yr CAGR: 5.6%
Net Income ↑2.1% YoY
$4.50B
Net Margin: 31.4%
Free Cash Flow ↑11.3% YoY
$4.08B
FCF Yield: 4.91%
EPS (Diluted) ↑8.2% YoY
$41.48
Basic: $43.07
Return on Equity Efficiency
14.4%
ROA: 11.1%

📊 Multi-Year Historical Performance & Trends

Financial Performance History Revenue, Net Income & Free Cash Flow
Margins Trend (%) Gross, Operating & Net Margins
Balance Sheet Strength Cash, Debt & Equity
Cash Flow Generation Operating Cash Flow vs CapEx vs FCF

📈 Year-over-Year (YoY) Growth History (REGN)

All monetary values in millions ($M)
Fiscal Year Revenue Revenue YoY Gross Profit Net Income Net Inc YoY Diluted EPS EPS YoY Div / Sh Div Yield Op. Cash Flow Free Cash Flow FCF YoY
FY 2016 $4,860.4M $4,665.8M $895.5M $7.70 0.00% $1,473.4M $961.5M
FY 2017 $5,872.2M +20.8% $5,669.7M $1,198.5M +33.8% $10.34 +34.3% 0.00% $1,307.1M $1,034.5M +7.6%
FY 2018 $6,710.8M +14.3% $6,276.7M $2,444.4M +104.0% $21.29 +105.9% 0.00% $2,195.1M $1,812.0M +75.2%
FY 2019 $7,863.4M +17.2% $7,081.2M $2,115.8M -13.4% $18.46 -13.3% 0.00% $2,430.0M $2,000.4M +10.4%
FY 2020 $8,497.1M +8.1% $7,377.2M $3,513.2M +66.0% $30.52 +65.3% 0.00% $2,618.1M $2,003.5M +0.2%
FY 2021 $16,071.7M +89.1% $10,771.7M $8,075.3M +129.9% $71.97 +135.8% 0.00% $7,081.3M $6,529.4M +225.9%
FY 2022 $12,172.9M -24.3% $10,612.5M $4,338.4M -46.3% $38.22 -46.9% 0.00% $5,014.9M $4,424.8M -32.2%
FY 2023 $13,117.2M +7.8% $11,301.4M $3,953.6M -8.9% $34.77 -9.0% 0.00% $4,594.0M $3,875.4M -12.4%
FY 2024 $14,202.0M +8.3% $12,231.5M $4,412.6M +11.6% $38.34 +10.3% 0.00% $4,420.5M $3,664.6M -5.4%
FY 2025 $14,342.9M +1.0% $6,277.9M $4,504.9M +2.1% $41.48 +8.2% $3.41 0.44% $4,978.9M $4,080.5M +11.3%
$

Valuation

Market Price $793.26
Market Cap $83.16B
Enterprise Value $82.03B
P/E Ratio 19.12
P/B Ratio 2.66
FCF Yield 4.91%
Dividend Yield 0.43%
Shares Outstanding 104,839,000
%

Profitability & Margins

Gross Margin 43.77%
Operating Margin 24.95%
Net Margin 31.41%
Return on Equity (ROE) 14.41%
Return on Assets (ROA) 11.11%
Asset Turnover 0.35x
Revenue 3-Yr CAGR 5.62%
🛡️

Financial Health & Liquidity

Current Ratio 4.13
Cash Ratio 0.71
Debt / Equity 0.064
Debt / Assets 0.049
Cash & Equivalents $3.12B
Total Debt $1.99B
Book Value / Share $298.14
💧

Cash Flow Efficiency

Operating Cash Flow $4.98B
Capital Expenditures (CapEx) $898.40M
Free Cash Flow $4.08B
OCF / Revenue 34.71%
FCF / Revenue 28.45%
FCF 3-Yr CAGR -2.66%
🏷️

Per Share Metrics

EPS (Diluted) $41.48
EPS (Basic) $43.07
Dividends / Share $3.41
Book Value / Share $298.14
EPS YoY Growth 8.19%
🏛️

Balance Sheet (FY 2025)

Total Assets $40.56B
Total Liabilities $9.30B
Stockholders' Equity $31.26B
Current Assets $18.02B
Current Liabilities $4.37B